Literature DB >> 18609189

Short-term moderate exercise programs reduce oxidative DNA damage as determined by high-performance liquid chromatography-electrospray ionization-mass spectrometry in patients with colorectal carcinoma following primary treatment.

Hubert Allgayer1, Robert W Owen, Jagadeesan Nair, Bertold Spiegelhalder, Jürgen Streit, Christoph Reichel, Helmut Bartsch.   

Abstract

OBJECTIVE: Oxidative DNA damage is believed to be involved in tumor formation and may be an important biomarker for malignant transition or relapse. A decrease of such damage has been observed in human and animal studies following dietary intervention and/or changes in lifestyle such as physical exercise at different levels of intensity. The purpose of this study was to carry out a clinical trial comparing the effects of a short-term (2 weeks) exercise program of moderate intensity (0.3-0.4 x maximal exercise capacity) (MI) versus high intensity (0.5-0.6 x maximal exercise capacity) (HI) on individual urinary excretion of 8-oxo-dG before and after completion of the exercise programs.
MATERIAL AND METHODS: In this short-term, prospective and randomized trial, 19 patients with colorectal cancer were allocated to the MI group following primary therapy and 29 to the HI group. Urinary 8-oxo-dG excretion concentration was determined by a highly sensitive detection method using high-performance liquid chromatography coupled to electrospray ionization mass spectrometry (HPLC-ESI-MS). Concentrations were determined immediately before and after completion of the exercise programs.
RESULTS: Using HPLC-ESI-MS, it was shown that MI exercise significantly reduced urinary 8-oxo-dG excretion levels from 8.47 +/- 1.99 to 5.81 +/- 1.45 (ng/mg creatinine, mean +/- SE, p = 0.02), whereas HI exercise resulted in a non-significant increase from 5.00 +/- 1.31 to 7.11 +/- 1.63 (ng/mg creatinine, p = 0.18). Clinical characteristics (gender, age, body mass index (BMI), diet, chemotherapy/irradiation) were not associated/correlated with urinary 8-oxo-dG levels.
CONCLUSIONS: By using HPLC-ESI-MS it was shown that short-term MI exercise after primary therapy in patients with colorectal cancer was associated with lower levels of urinary 8-oxo-dG, suggesting decreased oxidative DNA damage. In contrast, HI exercise tended to increase DNA damage. A prospective trial is now warranted to prove that reduced oxidative DNA damage lowers the risk of relapse of colorectal cancer in treated patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18609189     DOI: 10.1080/00365520701766111

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  30 in total

1.  Effects of aerobic training on oxidative status in postsurgical non-small cell lung cancer patients: a pilot study.

Authors:  Lee W Jones; Neil D Eves; Ivan Spasojevic; Frances Wang; Dora Il'yasova
Journal:  Lung Cancer       Date:  2010-09-21       Impact factor: 5.705

2.  The influence of high-intensity compared with moderate-intensity exercise training on cardiorespiratory fitness and body composition in colorectal cancer survivors: a randomised controlled trial.

Authors:  James L Devin; Andrew T Sax; Gareth I Hughes; David G Jenkins; Joanne F Aitken; Suzanne K Chambers; Jeffrey C Dunn; Kate A Bolam; Tina L Skinner
Journal:  J Cancer Surviv       Date:  2015-10-19       Impact factor: 4.442

Review 3.  Updated evidence in support of diet and exercise interventions in cancer survivors.

Authors:  Dorothy W Pekmezi; Wendy Demark-Wahnefried
Journal:  Acta Oncol       Date:  2010-11-24       Impact factor: 4.089

Review 4.  Effects and potential mechanisms of exercise training on cancer progression: a translational perspective.

Authors:  Allison S Betof; Mark W Dewhirst; Lee W Jones
Journal:  Brain Behav Immun       Date:  2012-05-17       Impact factor: 7.217

Review 5.  The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer.

Authors:  Amikar Sehdev; Bert H O'Neil
Journal:  Curr Treat Options Oncol       Date:  2015-09

6.  Regulation of colon cancer recurrence and development of therapeutic strategies.

Authors:  Shailender Singh Kanwar; Anuradha Poolla; Adhip Pn Majumdar
Journal:  World J Gastrointest Pathophysiol       Date:  2012-02-15

7.  Pre-post analysis of a social capital-based exercise adherence intervention for breast cancer survivors with moderate fatigue: a randomized controlled trial.

Authors:  Sue Kim; Yun Hee Ko; Yoonkyung Song; Min Jae Kang; Hyojin Lee; Sung Hae Kim; Justin Y Jeon; Young Up Cho; Gihong Yi; Jeehee Han
Journal:  Support Care Cancer       Date:  2020-02-26       Impact factor: 3.603

8.  Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.

Authors:  Brendan J Guercio; Sui Zhang; Fang-Shu Ou; Alan P Venook; Donna Niedzwiecki; Heinz-Josef Lenz; Federico Innocenti; Bert H O'Neil; James E Shaw; Blase N Polite; Howard S Hochster; James N Atkins; Richard M Goldberg; Kaori Sato; Kimmie Ng; Erin Van Blarigan; Robert J Mayer; Charles D Blanke; Eileen M O'Reilly; Charles S Fuchs; Jeffrey A Meyerhardt
Journal:  J Clin Oncol       Date:  2019-08-13       Impact factor: 44.544

9.  Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer.

Authors:  Mai Yamauchi; Paul Lochhead; Yu Imamura; Aya Kuchiba; Xiaoyun Liao; Zhi Rong Qian; Reiko Nishihara; Teppei Morikawa; Kaori Shima; Kana Wu; Edward Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs; Andrew T Chan; Shuji Ogino
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-29       Impact factor: 4.254

10.  Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood.

Authors:  Zhangfa Song; Guido von Figura; Yan Liu; Johann M Kraus; Chad Torrice; Patric Dillon; Masami Rudolph-Watabe; Zhenyu Ju; Hans A Kestler; Hanna Sanoff; Karl Lenhard Rudolph
Journal:  Aging Cell       Date:  2010-06-17       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.